Tongji University, with its long history and remarkable reputation, is one of the earliest national universities in China. It is a key university directly under the Ministry of Education and co-built with the Shanghai Municipal Government. The "School of Life Sciences and Technology" obtained approval from the Ministry of Education and the National Development and Reform Commission in 2002, becoming a national talent training base for life sciences and technology. Its research focuses on translational medicine related to biomedicine and major diseases, as well as fundamental research in areas such as molecular biology, cell biology, developmental biology, stem cells, and epigenetics, and bioinformatics.

On October 10, 2018, the School led by Tongji University successfully obtained approval for the construction of the "Frontier Science Center for Cell Stemness and Fate Editing" from the Ministry of Education. On June 5, 2019, the School, also led by Tongji University, got approval to establish the " National Stem Cell Translational Resource Center," becoming one of the two stem cell resource banks approved by the country.

Yuanvore Medicine and the School of Life Sciences and Technology at Tongji University have established scientific research cooperation aiming to develop novel and efficient reprogramming methods of non-integrating genes, and to establish both research-grade and clinical-grade pluripotent stem cell banks for applications in constructing in vitro disease model, drug screening, and cell-based drug development.

ShanghaiTech University is jointly established and constructed by the Shanghai Municipal People’s Government and the Chinese Academy of Sciences. It cooperates with nearly 20 top universities worldwide and aims to be a small-scale, high-level, international research-oriented and innovative elite university. The School of Life Science and Technology is dedicated to solving scientific problems related to human health and aims to build a research-oriented college that reaches international high standards. It actively introduces outstanding talents in basic life science research from domestic and overseas and explores the development model that combines teaching, research, and transformation, contributing to the construction of the Shanghai Zhangjiang Comprehensive National Science Center, cultivating high-end research talents that adapt to the future development of life sciences, as well as new types of technical talents that meet the needs of health medicine.

Yuanvore Medicine has established scientific research cooperation with the School of Life Science and Technology at ShanghaiTech University, focusing on the research direction of iPSC directed differentiation. By combining developmental biology, transcriptomics, epigenomics, proteomics, and other technologies, it develops efficient differentiation methods and conducts large-scale production process development to provide high-quality cell supply for the application of iPSC.

Shanghai Sixth People's Hospital was founded in 1904. It is a large-scale third-level A comprehensive teaching hospital integrating clinical practice, scientific research and teaching. It is a leading research hospital in the country and even the world. It leads biomedical reform and promotes cross-cooperation in multiple fields, and has made a large number of original contributions in clinical diagnosis and treatment, scientific research, etc.

In November 2024, Yuanvore Medicine and Shanghai Sixth People's Hospital officially launched a metabolic disease cooperation project, which is also the first time in the world that iPSC technology has been applied to treat such diseases.

Yuanvore Medicine has established scientific research cooperation with the Sixth People's Hospital of Shanghai City, focusing on reaching in-depth cooperation in cell development and differentiation methods, in vitro functional testing technology development, model animal development, cell drug research and development, quality standards, etc., and is committed to working together to create and explore new fields of iPSC technology application in the treatment of metabolic system diseases, and promote the introduction of safe, effective, and accessible stem cell drugs into clinical practice.